Immune checkpoint inhibitors (ICIs), immunomodulatory antibodies that are used to enhance
the immune system, have substantially improved the prognosis of patients with advanced …

Immune checkpoint inhibitors (ICI) targeting CTLA-4 and the PD-1/PD-L1 axis have
unprecedentedly improved global prognosis in several types of cancers. However, they are …

Background. We studied the variation in molecular T cell–mediated rejection (TCMR) activity
in kidney transplant indication biopsies and its relationship with histologic lesions …

Cancer is a leading cause of death in patients with kidney transplantation. Patients with
kidney transplants are 10-to 200-times more likely to develop cancers after transplant than …

Background Solid organ transplantation (SOT) is a treatment method for end-stage organ
diseases and improve their life quality, while using long-term immunosuppressant drugs …

Despite recent advances in the management of urothelial cancer (UC), cisplatin-based
combination chemotherapy regimens remain critical. However, their use can be complicated …

Immune checkpoint inhibitors (ICIs) are monoclonal antibody drugs that block the binding of
specific regulatory proteins located on T cells. Cytotoxic T lymphocyte-associated antigen-4 …

Discussion The incidence of GIS ranges from 12 to 37% in adults [6]. It mostly occurs within
the first year after graft loss [11]. In a report with 74 patients who underwent graft …

Nivolumab and ipilimumab are immune checkpoint inhibitors. Combination therapy with
these two drugs has been shown to improve the outcome of advanced renal cell carcinoma …

Данный обзор литературы посвящен снижению функции почек при почечно-клеточном
раке. По данным международных исследований, ряд пациентов на момент дебюта …